479 related articles for article (PubMed ID: 34731180)
41. Inhibition of Glucose Transporters and Glutaminase Synergistically Impairs Tumor Cell Growth.
Reckzeh ES; Karageorgis G; Schwalfenberg M; Ceballos J; Nowacki J; Stroet MCM; Binici A; Knauer L; Brand S; Choidas A; Strohmann C; Ziegler S; Waldmann H
Cell Chem Biol; 2019 Sep; 26(9):1214-1228.e25. PubMed ID: 31303578
[TBL] [Abstract][Full Text] [Related]
42. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
43. In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma.
Kaushik AK; Tarangelo A; Boroughs LK; Ragavan M; Zhang Y; Wu CY; Li X; Ahumada K; Chiang JC; Tcheuyap VT; Saatchi F; Do QN; Yong C; Rosales T; Stevens C; Rao AD; Faubert B; Pachnis P; Zacharias LG; Vu H; Cai F; Mathews TP; Genovese G; Slusher BS; Kapur P; Sun X; Merritt M; Brugarolas J; DeBerardinis RJ
Sci Adv; 2022 Dec; 8(50):eabp8293. PubMed ID: 36525494
[TBL] [Abstract][Full Text] [Related]
44. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
45. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
[TBL] [Abstract][Full Text] [Related]
46. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
[TBL] [Abstract][Full Text] [Related]
47. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
[TBL] [Abstract][Full Text] [Related]
48. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
Cella D; Escudier B; Tannir NM; Powles T; Donskov F; Peltola K; Schmidinger M; Heng DYC; Mainwaring PN; Hammers HJ; Lee JL; Roth BJ; Marteau F; Williams P; Baer J; Mangeshkar M; Scheffold C; Hutson TE; Pal S; Motzer RJ; Choueiri TK
J Clin Oncol; 2018 Mar; 36(8):757-764. PubMed ID: 29377755
[TBL] [Abstract][Full Text] [Related]
49. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care.
Castellano D; Pablo Maroto J; Benzaghou F; Taguieva N; Nguyen L; Clary DO; Jonasch E
Cancer Treat Rev; 2020 Sep; 89():102062. PubMed ID: 32659623
[TBL] [Abstract][Full Text] [Related]
50. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.
Shroff EH; Eberlin LS; Dang VM; Gouw AM; Gabay M; Adam SJ; Bellovin DI; Tran PT; Philbrick WM; Garcia-Ocana A; Casey SC; Li Y; Dang CV; Zare RN; Felsher DW
Proc Natl Acad Sci U S A; 2015 May; 112(21):6539-44. PubMed ID: 25964345
[TBL] [Abstract][Full Text] [Related]
51. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
Motzer RJ; Escudier B; Powles T; Scheffold C; Choueiri TK
Br J Cancer; 2018 May; 118(9):1176-1178. PubMed ID: 29576624
[TBL] [Abstract][Full Text] [Related]
52. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
Scott AJ; Arcaroli JJ; Bagby SM; Yahn R; Huber KM; Serkova NJ; Nguyen A; Kim J; Thorburn A; Vogel J; Quackenbush KS; Capasso A; Schreiber A; Blatchford P; Klauck PJ; Pitts TM; Eckhardt SG; Messersmith WA
Mol Cancer Ther; 2018 Oct; 17(10):2112-2122. PubMed ID: 30026382
[TBL] [Abstract][Full Text] [Related]
53. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
[TBL] [Abstract][Full Text] [Related]
54. Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
Sourbier C; Ricketts CJ; Liao PJ; Matsumoto S; Wei D; Lang M; Railkar R; Yang Y; Wei MH; Agarwal P; Krishna M; Mitchell JB; Trepel JB; Neckers L; Linehan WM
Sci Rep; 2019 Dec; 9(1):18409. PubMed ID: 31804603
[TBL] [Abstract][Full Text] [Related]
55. Acidosis-induced metabolic reprogramming in tumor cells enhances the anti-proliferative activity of the PDK inhibitor dichloroacetate.
Schoonjans CA; Joudiou N; Brusa D; Corbet C; Feron O; Gallez B
Cancer Lett; 2020 Feb; 470():18-28. PubMed ID: 31812695
[TBL] [Abstract][Full Text] [Related]
56. Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.
Damiano V; Rosa R; Formisano L; Nappi L; Gelardi T; Marciano R; Cozzolino I; Troncone G; Agrawal S; Veneziani BM; De Placido S; Bianco R; Tortora G
Br J Cancer; 2013 Apr; 108(8):1616-23. PubMed ID: 23571736
[TBL] [Abstract][Full Text] [Related]
57. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
[TBL] [Abstract][Full Text] [Related]
58. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.
Grassi P; Verzoni E; Ratta R; Mennitto A; de Braud F; Procopio G
Drug Des Devel Ther; 2016; 10():2167-72. PubMed ID: 27462141
[TBL] [Abstract][Full Text] [Related]
59. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
Okazaki A; Gameiro PA; Christodoulou D; Laviollette L; Schneider M; Chaves F; Stemmer-Rachamimov A; Yazinski SA; Lee R; Stephanopoulos G; Zou L; Iliopoulos O
J Clin Invest; 2017 May; 127(5):1631-1645. PubMed ID: 28346230
[TBL] [Abstract][Full Text] [Related]
60. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
Tannir NM; Schwab G; Grünwald V
Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]